|
業務類別
|
Medical Devices |
|
業務概覽
|
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease. |
| 公司地址
| 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025 |
| 電話號碼
| +1 877 266-1144 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sightsciences.com |
| 員工數量
| 216 |
| Mr. Paul Badawi |
Director, President and Chief Executive Officer |
美元 640.00K |
04/03/2026 |
| Dr. David Badawi, M.D. |
Chief Technology Officer and Director |
-- |
04/03/2026 |
| Mr. Brenton Taylor |
Executive Vice President, Operations |
-- |
23/04/2025 |
| Ms. Alison Bauerlein |
Chief Operating Officer |
美元 450.00K |
06/11/2025 |
| Mr. James Rodberg |
Chief Financial Officer, Principal Accounting Officer and Treasurer |
-- |
04/03/2026 |
| Mr. Jeremy B. Hayden |
Chief Legal Officer |
美元 420.00K |
23/04/2025 |
| Dr. Manohar K. Raheja |
Executive Vice President, Research and Development |
-- |
23/04/2025 |
|
|
| Dr. Tamara R. Fountain, M.D. |
Independent Director |
04/03/2026 |
| Mr. Staffan Encrantz |
Non-Executive Chairperson of The Board |
04/03/2026 |
| Mr. Paul Badawi |
Director, President and Chief Executive Officer |
04/03/2026 |
| Dr. David Badawi, M.D. |
Chief Technology Officer and Director |
04/03/2026 |
| Ms. Catherine Mazzacco |
Independent Director |
04/03/2026 |
| Mr. Gerhard F. Burbach |
Director |
04/03/2026 |
| Mr. Donald J. Zurbay |
Independent Director |
04/03/2026 |
|
|
|
|
